Kerendia

News

Data builds behind Bayer's Kerendia in kidney disease

Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.

News

Bayer gets sought-after heart failure use for Kerendia

Bayer's Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's blockbuster sales prospects.

News

Bayer trial combines two top drugs for kidney disease

Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.

News

Bayer CEO confident firm can cope with Xarelto hit

Bayer's CEO says new product launches will offset the decline in sales of anticoagulant Xarelto over the course of 2025.

News

Kerendia pill bottle with tablets on surface

Bayer files finerenone in EU for heart failure

Bayer has filed its mineralocorticoid receptor antagonist finerenone as a treatment heart failure in the EU, but can it meet blockbuster sales hopes?

News

Kerendia works in heart failure, but how might it be used?

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but th

Data builds behind Bayer's Kerendia in kidney disease

Bayer gets sought-after heart failure use for Kerendia

Bayer trial combines two top drugs for kidney disease

Bayer CEO confident firm can cope with Xarelto hit

Bayer files finerenone in EU for heart failure

Kerendia works in heart failure, but how might it be used?

After setback, Rhythm gets good news on Imcivree from FDA

Using AI-driven synthetic personas to take your insights fur...

Kerendia

Editor's Picks